NASDAQ: VBIOValion Bio Inc Stock
$0.53-0.01 (-1.85%)
Updated Nov 10, 2026
VBIO Price
$0.53
Fair Value Price
N/A
Market Cap
$469.54k
52 Week Low
$0.47
52 Week High
$67.50
P/E
0x
P/B
0.11x
P/S
-11.26x
PEG
N/A
Dividend Yield
N/A
Revenue
-$156.00k
Earnings
-$18.75M
Gross Margin
66.7%
Operating Margin
11,067.31%
Profit Margin
12,019.2%
Debt to Equity
4.85
Operating Cash Flow
-$15M
Beta
1
Next Earnings
Nov 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
VBIO Overview
Tivic Health Systems Incorporated is a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, a medical device intended to relieve sinus and nasal inflammation. The company sells its products through its own website and other online retailers. Tivic Health Systems was incorporated in 2016 and is headquartered in Hayward, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VBIO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VBIO
Ranked#231 of 450
Ranked#231 of 450
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $15.83 | A | |
| $916.06 | A | |
| $424.00 | A |
Be the first to know about important VBIO news, forecast changes, insider trades & much more!
VBIO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VBIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VBIO is good value based on its book value relative to its share price (0.11x), compared to the US Biotechnology industry average (5.28x)
P/B vs Industry Valuation
VBIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VBIO due diligence checks available for Premium users.
Valuation
VBIO fair value
Fair Value of VBIO stock based on Discounted Cash Flow (DCF)
Price
$0.53
Fair Value
$5.36
Undervalued by
90.11%
VBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
17.34x
Market
41.12x
VBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.11x
Industry
5.28x
VBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VBIO's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.1M
Profit Margin
0%
VBIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VBIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$32.5M
Liabilities
$20.6M
Debt to equity
4.85
VBIO's short-term assets ($3.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VBIO's long-term liabilities ($17.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VBIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.3M
Investing
-$57.0k
Financing
$231.0k
VBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VBIO vs Biotech Stocks
Valion Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.